Adding repeated PIPAC chemotherapy to standard treatment for advanced ovarian cancer
Tests repeated PIPAC chemotherapy added to standard treatment in women with advanced ovarian cancer.
Plain-language title generated from the registry record
Registry title: Intensification Treatment of Ovarian Cancer by PIPAC
Key facts
- Where
- Balashikha, RussiaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07514494, who can take part
Where in Russia
- Moscow Regional Oncological DispensaryBalashikha, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Moscow Regional Oncological Dispensary
- Trial code
- NCT07514494
- Record updated
- 7 April 2026
- Original description
The goal of this clinical trial is to learn whether repeated cisplatin-based PIPAC added to standard TC chemotherapy can improve outcomes in women aged 18-75 years with newly diagnosed FIGO IIIB-IIIC epithelial ovarian cancer and visually detectable peritoneal carcinomatosis. The main questions are whether repeated PIPAC increases the rate of complete surgical cytoreduction (CRS R0) and whether it improves disease control, survival outcomes, and safety compared with standard combined treatment including a single PIPAC procedure. Participants will undergo screening, intraoperative randomization, systemic chemotherapy, PIPAC procedures according to study arm, interval cytoreductive surgery, protocol-specified postoperative treatment if needed, and regular follow-up assessments.Read full original descriptionShow less
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as a Component of Combined Treatment in Patients With Advanced Epithelial Ovarian Cancer and Peritoneal Carcinomatosis: A Randomized Phase II Trial (PrimPIPAC)
The goal of this clinical trial is to learn whether repeated cisplatin-based PIPAC added to standard TC chemotherapy can improve outcomes in women aged 18-75 years with newly diagnosed FIGO IIIB-IIIC epithelial ovarian cancer and visually detectable peritoneal carcinomatosis. The main questions are whether repeated PIPAC increases the rate of complete surgical cytoreduction (CRS R0) and whether it improves disease control, survival outcomes, and safety compared with standard combined treatment including a single PIPAC procedure. Participants will undergo screening, intraoperative randomization, systemic chemotherapy, PIPAC procedures according to study arm, interval cytoreductive surgery, protocol-specified postoperative treatment if needed, and regular follow-up assessments.
Inclusion: Female, age 18-75 years; Histologically verified ovarian cancer with peritoneal carcinomatosis; FIGO stage IIIB or IIIC; visually detectable peritoneal carcinomatosis; Peritoneal metastatic involvement documented preoperatively by ultrasound, CT, MRI, PET-CT, or equivalent imaging; Ability to comply with protocol procedures and provide written informed consent.
Exclusion: Severe concomitant disease in exacerbation or decompensation; Mucinous ovarian carcinoma or another active malignant neoplasm, except malignancies in clinical remission for more than 2 years; Pronounced adhesive disease of the abdominal cavity; Any condition precluding safe PIPAC or protocol execution, including hollow-organ perforation, gastrointestinal resection with anastomosis, or repair of a hollow-viscus defect; Age > 75 years; ECOG 3-4; cachexia with BMI <= 16; Extra-abdominal metastases, including metastatic pleuritis; Pregnancy or breastfeeding; Positive BRCA1 or BRCA2 status; Refusal of treatment at any study stage.